Related Experiment Video
Updated: Aug 9, 2025

Treatment with Locking Intramedullary Nailing for Intertrochanteric Fracture of the Femur Utilizing a New Awl with a Distal Positioner
Published on: June 6, 2025
Retrograde Nailing for Extremely Proximal Fractures of the Femoral Shaft
Samantha Nino1, Reese Courington, Patrick Brooks
1Orlando Regional Medical Center, Orlando, FL.
Objectives:
To report the results of retrograde intramedullary nailing (RIMN) for the treatment of extremely proximal femur fractures.
Design:
Retrospective cohort study.
Setting:
Level I trauma center.
Patients/Participants:
63 patients with femoral shaft fractures involving the anatomic region within 10 centimeters of the inferior border of the lesser trochanter, which were treated with retrograde intramedullary nailing.
Intervention:
Retrograde intramedullary femoral nail.
Main Outcome Measurements:
Time to union, nonunion, malunion, and unplanned reoperation.
Results:
Between 2009 and 2020, 63 fractures were followed up to fracture union, reoperation, or a minimum of 1 year clinically. The mean follow-up was 32 months, and 48 (76%) of the patients were followed up beyond 1 year clinically. The mean patient age was 34 years (range 18-84 years), and the mean BMI was 27 (range 14-45) kg/m 2 . Forty (64%) patients were polytraumatized. Clinical and radiographic union was achieved in 59 (94%) fractures after index operation at a mean time to union of 22 weeks (range 9-51 weeks). Delayed union requiring nail dynamization occurred in 1 (2%) instance. Malreduction was noted in 1 (2%) patient with a 12-degree flexion deformity that resulted in nonunion. In total, there were 3 (5%) nonunions requiring revision surgery, 1 treated with retrograde exchange nailing and 2 revised to cephalomedullary nails; all were united after revision.
Conclusions:
Retrograde intramedullary nailing can be an effective treatment strategy for extremely proximal femur fractures when necessary. Our series demonstrated a high rate of union and a low rate of malalignment and complications.
Level Of Evidence:
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

